Head & Neck Cancers | Specialty

Dr. Saba on Investigational Deintensification Approaches in HPV-Related HNSCC

August 15th 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses investigational deintensification approaches in HPV-related oropharyngeal squamous cell carcinoma.

Dr. Saba on Treatment Deintensification in HPV-Related Oropharyngeal Squamous Cell Carcinoma

August 1st 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses treatment deintensification for patients with HPV-related oropharyngeal squamous cell carcinoma.

Dr. Rischin on KEYNOTE-048 Results in Head and Neck Squamous Cell Carcinoma

August 1st 2019

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the phase III KEYNOTE-048 trial, which examines pembrolizumab or pembrolizumab plus chemotherapy versus EXTREME as first-line therapy for patients with recurrent/metastatic head and neck squamous cell carcinoma.

Dr. Saba on Improving Cancer Detection Rates in HNSCC

June 27th 2019

Nabil F. Saba, MD, FACP, discussed the role of general practitioners in maintaining the health of their patients with cancer and how to better diagnosis select types of head and neck cancer.

FDA Approves Single-Agent Pembrolizumab or Plus Chemo for Frontline HNSCC

June 11th 2019

The FDA has approved pembrolizumab (Keytruda) for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma as monotherapy whose tumors express PD-L1 (composite positive score [CPS] ≥1) and also in combination with platinum and fluorouracil (FU) for this patient population, irrespective of PD-L1 expression.

ASCO 2019: Dr. Plimack Highlights Practice-Changing Data for Genitourinary Cancers

June 2nd 2019

ASCO 2019: Dr. Ferris Discusses the Latest Data in Head and Neck Cancer

June 2nd 2019

Dr. Tolaney Highlights New Breast Cancer Combination Therapies

June 2nd 2019

ASCO 2019: Dr. Monk on Promising Abstracts in Gynecologic Malignancies

June 2nd 2019

ASCO 2019: Dr. Horn Highlights Progress in Lung Cancer

June 2nd 2019

ASCO 2019: Dr. Shah Covers Potentially Practice-Changing GI Cancer Studies

June 2nd 2019

ASCO 2019: Dr. Tagawa Highlights Key Prostate Cancer Data

June 2nd 2019

ASCO 2019: Dr. Rajkumar Highlights Practice-Changing Multiple Myeloma Studies

June 2nd 2019

OncLive News Network On Location: In Chicago Tuesday, June 4

June 2nd 2019

OncLive News Network On Location: In Chicago Monday, June 3

June 2nd 2019

OncLive News Network On Location: In Chicago Sunday, June 2

June 2nd 2019

OncLive News Network On Location: In Chicago Saturday, June 1

June 2nd 2019

Addressing Unmet Needs in Medullary Thyroid Cancer

June 1st 2019

Rozita Yarmand, PhD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders-Research, The University of Texas MD Anderson Cancer Center, discusses unmet needs in medullary thyroid cancer.

Dr. Cohen on the Era Before Immunotherapy in Head and Neck Cancer

May 29th 2019

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the treatment era before immunotherapy in head and neck cancer.

Montefiore Study May Help Establish Patient Criteria for Proton Therapy

May 21st 2019

In an effort to build more sophisticated protocols that keep QoL and cost questions at the forefront, Montefiore Einstein Center for Cancer Care and Albert Einstein College of Medicine’s Institute for Onco-Physics created a mathematical model to identify the optimal candidates for proton therapy, the most modern form of radiation therapy for patients with head and neck cancers.